AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Avalo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.59+0.32 (+2.84%)
Close on Oct 19, 2026
- Market cap
- $505.35M
- P/E (TTM)
- –
- Dividend yield
- –
Avalo Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $59.00K | $441.00K | $304.00K | $291.00K | $934.00K | $1.41M | $2.08M | $2.28M | $2.63M | $3.36M | $2.82M | $3.74M | 100.0% | -86.6% |
| License revenue | – | – | – | – | – | $516.00K | – | – | – | $14.69M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Avalo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.